Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

Glaucoma, Visual Field Loss, and Their Association With Life Space in Older Adults

NCT04396002 · View on ClinicalTrials.gov ↗

Study Summary

Mobility refers to a person's purposeful movement through the environment from one place to another and can be conceptualized as a continuum from bed bound (immobility) on one extreme to making excursions to distant locations on the other extreme. Primary open-angle glaucoma (POAG) is a chronic, progressive optic neuropathy that can lead to gradual loss of vision in the peripheral field and central vision. Older adults with POAG have an increased risk for motor vehicle collisions and falls. Moreover, existing studies suggest that patients with POAG exhibit more postural sway while standing as measured by a balance platform and also tend to walk more slowly than those who are normally sighted and free of ocular disease. While these disturbances likely influence mobility, there has been little research directly assessing the impact of POAG on mobility. This study will assess the impact of POAG on life space (one aspect of mobility) and will determine whether difficulties with life space are associated with difficulties experienced under conditions of dim lighting.

Interventions

  • DIAGNOSTIC_TEST Life Space Questionnaire
  • DIAGNOSTIC_TEST Low Luminance Questionnaire
  • DIAGNOSTIC_TEST Contrast sensitivity under dim illumination
  • DIAGNOSTIC_TEST Visual field under dim illumination (MAIA)
  • DIAGNOSTIC_TEST Macular Pigment Optical Density (MPOD)

Study Locations (1)

Alabama

  • University of Alabama Birmingham — Birmingham

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2019-06-01
Est. Completion 2026-05-30

Sponsor

University of Alabama at Birmingham

1,315 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04396002

The ClinicalTrials.gov registry entry for NCT04396002 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,315 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Primary Open Angle Glaucoma appearing as the primary indexed condition, and to 5 interventions — of which Life Space Questionnaire is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT04396002 reports 1 study location spanning 1 distinct geographic area — top geographies include Alabama. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT04396002 about?

NCT04396002 is a clinical study titled "Glaucoma, Visual Field Loss, and Their Association With Life Space in Older Adults". Mobility refers to a person's purposeful movement through the environment from one place to another and can be conceptualized as a continuum from bed bound (immobility) on one extreme to making excursions to distant locations on the other extreme. Primary open-angle glaucoma (POAG) is a chronic, pro...

What is the current status of trial NCT04396002?

This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2019-06-01. Estimated completion is 2026-05-30.

What conditions does trial NCT04396002 study?

This clinical trial studies the following conditions: Primary Open Angle Glaucoma. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT04396002?

The interventions under investigation include: Life Space Questionnaire (DIAGNOSTIC_TEST), Low Luminance Questionnaire (DIAGNOSTIC_TEST), Contrast sensitivity under dim illumination (DIAGNOSTIC_TEST), Visual field under dim illumination (MAIA) (DIAGNOSTIC_TEST), Macular Pigment Optical Density (MPOD) (DIAGNOSTIC_TEST). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT04396002?

This trial is sponsored by University of Alabama at Birmingham, which has 1,315 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT04396002 being conducted?

This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial